Direct costs of care in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt for bleeding esophageal varices in cirrhosis--Part 4

Marshall J Orloff, Jon I Isenberg, Henry O Wheeler, Kevin S Haynes, Horacio Jinich-Brook, Roderick Rapier, Florin Vaida, Robert J Hye, Marshall J Orloff, Jon I Isenberg, Henry O Wheeler, Kevin S Haynes, Horacio Jinich-Brook, Roderick Rapier, Florin Vaida, Robert J Hye

Abstract

Background: Emergency treatment of bleeding esophageal varices (BEV) in cirrhotic patients is of prime importance because of the high mortality rate surrounding the episode of acute bleeding. Nevertheless, there is a paucity of randomized controlled trials of emergency surgical therapy and no reports of the costs of any of the widely used forms of emergency treatment. The important issue of direct costs of care was examined in a randomized controlled trial that compared endoscopic sclerotherapy (EST) to emergency portacaval shunt (EPCS).

Methods: Two hundred eleven unselected consecutive patients with ultimately biopsy-proven cirrhosis and endoscopically proven acute BEV were randomized to EST (n = 106) or EPCS (n = 105). Diagnostic workup was completed, and EST or EPCS was initiated within 8 h. Criteria for failure of EST or EPCS were clearly defined, and crossover rescue treatment was applied, when primary therapy failed. Ninety-six percent of patients underwent more than 10 years follow-up, or until death. Complete charges for all aspects of care were obtained continuously for more than 10 years.

Results: Direct charges for all aspects of care were significantly lower in patients treated by EPCS than in patients treated by emergency EST followed by long-term repetitive sclerotherapy. Charges per patient, per year of treatment, and per year in each child's risk class were significantly lower in patients randomized to EPCS. Charges in patients who failed endoscopic sclerotherapy and underwent a rescue portacaval shunt were significantly higher than the charges in both the unshunted sclerotherapy patients and the patients randomized to EPCS. This result was particularly noteworthy given the widespread practice of using surgical portacaval shunt as rescue treatment only when all other forms of therapy have failed.

Conclusions: In this randomized controlled trial of emergency treatment of acute BEV, EPCS was significantly superior to EST with regard to direct costs of care as reflected in charges for care as well as in survival rate, control of bleeding, and incidence of portal-systemic encephalopathy. These results provide support for the use of EPCS as a first line of emergency treatment of BEV in cirrhosis.

Trial registration: ClinicalTrials.gov NCT00690027.

Figures

Fig. 1
Fig. 1
The overall design and conduct of the prospective randomized controlled trial is shown in a Consort Flow Diagram ,
Fig. 2
Fig. 2
Total charges for patients randomized to endoscopic sclerotherapy (EST; n = 106) or emergency portacaval shunt (EPCS; n = 105) treatment of acutely bleeding esophageal varices

References

    1. Orloff MJ. Portal hypertension and portacaval shunt. In: Souba W, Wilmore D, editors. Surgical research. San Diego: Harcourt Brace; 2001. pp. 637–701.
    1. Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. J Am Coll Surg. 2009;209:25–45. doi: 10.1016/j.jamcollsurg.2009.02.059.
    1. Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ. Portal-systemic encephalopathy in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt treatment of acutely bleeding esophageal varices in cirrhosis. Ann Surg. 2009;250:598–610.
    1. Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ. Emergency portacaval shunt versus rescue portacaval shunt in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis—Part 3. J Gastrointest Surg 2010; in press.
    1. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–1991. doi: 10.1001/jama.285.15.1987.
    1. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134:663–694.
    1. Finkler SA. The distinction between costs and charges. Ann Intern Med. 1982;96:102–109.
    1. Orloff MJ, Ellwein LB, Folkman MJ, Kirklin JW, Mankin HJ, Najarian JS, Reemtsma K, Shires GT. Contributions of surgical research to health care. In: Zuidema G, editor. Study on surgical services for the United States. Baltimore: Lewis Advertising Co; 1975. pp. 153–184.
    1. Orloff MJ. Contributions of research in surgical technology to health care. In: Egdahl RH, Garman PM, editors. Technology and the Quality of Health Care. Rockville, MD: Aspens Systems Corp.; 1978. pp. 71–103.
    1. Cello P, Grendell JH, Crass RA, Trunkey DD, Cobb EE, Heilbron DC. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. N Engl J Med. 1984;311:1589–1594. doi: 10.1056/NEJM198412203112501.
    1. Cello JP, Grendell JH, Crass RA, Weber TE, Trunkey DD. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. N Engl J Med. 1987;316:11–15. doi: 10.1056/NEJM198701013160103.
    1. Orloff MJ, Orloff MS, Orloff SL, Rambotti M, Girard B. Three decades of experience with emergency portacaval shunt for acutely bleeding esophageal varices in 400 unselected patients with cirrhosis of the liver. J Am Coll Surg. 1995;180:257–272.
    1. Cello JP, Ring EJ, Olcott EW, Koch J, Gordon R, Sandhu J, Morgan DR, Ostroff JW, Rockey DC, Bacchetti P, LaBerge J, Lake JR, Somberg K, Doherty C, Davila M, McQuaid K, Wall SD. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. Ann Intern Med. 1997;126:858–865.
    1. Rosemurgy AS, II, Bloomston M, Zervox EE, Goode SE, Pencev D, Zweibel B, Black TJ. Transjugular intrahepatic portosystemic shunt versus H-graft portacaval shunt in the management of bleeding varices: a cost-benefit analysis. Surgery. 1997;122(4):794–799. doi: 10.1016/S0039-6060(97)90089-1.
    1. Rosemurgy AS, Zervos EE, Bloomston M, Durkin AJ, Clark WC, Goff S. Post-shunt resource consumption favors small-diameter prosthetic H-graft portacaval shunt over TIPS for patients with poor hepatic reserve. Ann Surg. 2003;237(6):820–825.
    1. Gralnek IM, Jensen DM, Kovacs TO, Jutabha R, Machicado GA, Gornbein J, King J, Cheng S, Jensen ME. The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Hepatology. 1999;29:44–50. doi: 10.1002/hep.510290141.
    1. Talwalker JA. Cost effectivenss of treating esophageal varices. Clin Liver Dis. 2006;10:679–689. doi: 10.1016/j.cld.2006.11.001.
    1. Plevris JN, Haynes PC. Treating bleeding oesophageal varices with vasoactive agents: good value for money? Curr Med Res Opin. 2007;23(7):1745–1747. doi: 10.1185/030079907X210859.
    1. Imperiale TF, Klein RW, Chalasani N. Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology. 2007;45:870–878. doi: 10.1002/hep.21605.
    1. Sonnenberg FA, Beck JR. Markov models in medical decision-making: a practical guide. Med Decis Making. 1993;13:322–338. doi: 10.1177/0272989X9301300409.
    1. Henderson JM, Boyer TD, Kutner MH, Galloway JR, Rikkers LF, Jeffers LJ, Abu-Elmagd K, Connor J, DIVERT Study Group Gastroenterology. 2006;130:1643–1651. doi: 10.1053/j.gastro.2006.02.008.
    1. Boyer TD, Henderson JM, Heerey AM, Arrigain S, Konig V, Connor J, Abu-Elmagd K, Galloway J, Rikkers LF, Jeffers L, DIVERT Study Group Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt. J Hepatol. 2008;48:407–414. doi: 10.1016/j.jhep.2007.08.014.
    1. Krige JE, Shaw JM, Bornman PC. The evolving role of endoscopic treatment of esophageal varices. Wld J Surg. 2005;29:966–973. doi: 10.1007/s00268-005-0138-2.
    1. Sorbi D, Gostout CJ, Peura D, Johnson D, Lanza F, Foutch PG, Schleck CD, Zinsmeister AR. An assessment of the management of acute bleeding varices: a multicenter prospective member-based study. Am J Gastroenterol. 2003;98:2424–2434. doi: 10.1111/j.1572-0241.2003.t01-1-07705.x.
    1. Gralnek IM, Jensen DM, Kovacs TOG, Jutabha R, Gornbein J, Cheng S, King J, Jensen ME. The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Hepatology. 1999;29:44–50. doi: 10.1002/hep.510290141.
    1. Triantos CK, Goulis J, Patch D, Papatheodoridis GV, Leandro G, Samonakis D, Cholongitas E, Burroughs AK. An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy. 2006;38:797–808. doi: 10.1055/s-2006-944566.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다